PRRT2 and cancer: In vivo studies in mice demonstrated that the efficacy of 18 was inhibited by the PKC inhibitor bisindolylmaleimide 1 (BIM-1), suggesting that the anti-cancer activity of 18 is PKC-dependent [63].